ProCE Banner Activity

Insights sobre novos dados com inibidores de BTK para LLC e LCM da Reunião Anual da SOHO 2022

Clinical Thought

Neste comentário, dois especialistas discutem as implicações dos dados de ensaios clínicos apresentados na Reunião Anual da SOHO 2022 sobre tratamentos baseados em inibidores de BTK para pacientes com leucemia linfocítica crônica e linfoma de células do manto.

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Kami Maddocks

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS: consulting/advisory/speaker: AstraZeneca, Bayer, BeiGene, BioAscend, Bristol-Myers Squibb, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Foresight Diagnostics, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys, N-Power, Pharmacyclics/Janssen, SeaGen; stock options: Foresight Diagnostics, N-Power; research funding (institution): 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceuticals, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Kami Maddocks, MD: consultant/advisor/speaker: AbbVie, Acerta, ADC Therapeutics, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Genmab, Gilead, Incyte, Janssen, Kite, Lilly, MorphoSys, Pharmacyclics.